| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2010.30.5235 |
| P698 | PubMed publication ID | 21220614 |
| P50 | author | Arthur R Bradwell | Q47423967 |
| Helen J Lachmann | Q56426736 | ||
| P2093 | author name string | Loveleen Bansi | |
| Ashutosh D Wechalekar | |||
| Julian D Gillmore | |||
| Philip N Hawkins | |||
| Jennifer H Pinney | |||
| Simon D J Gibbs | |||
| Nancy L Wassef | |||
| Dorota Rowczenio | |||
| Janet A Gilbertson | |||
| Prayman T Sattianayagam | |||
| Emanuela Orlandi | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| AL amyloidosis | Q4652470 | ||
| P304 | page(s) | 674-681 | |
| P577 | publication date | 2011-01-10 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Outcome in renal Al amyloidosis after chemotherapy | |
| P478 | volume | 29 |
| Q36892637 | A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? |
| Q61657837 | A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis |
| Q36392233 | Al amyloidosis |
| Q86511304 | Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement |
| Q48629376 | Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure |
| Q40918755 | Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement |
| Q48847335 | Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant |
| Q27023177 | Concurrent nephrotic syndrome and acute renal failure caused by chronic lymphocytic leukemia (CLL): a case report and literature review |
| Q38326729 | Diagnosis of monoclonal gammopathy of renal significance |
| Q44907517 | End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. |
| Q55058605 | Guidelines on the diagnosis and investigation of AL amyloidosis. |
| Q38970608 | Immunoglobulin Light Chain Systemic Amyloidosis |
| Q26827340 | Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment |
| Q34448455 | Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment |
| Q38928383 | Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment |
| Q41582133 | Impact of monitoring longitudinal systolic strain changes during serial echocardiography on outcome in patients with AL amyloidosis. |
| Q30278687 | Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study |
| Q42543905 | Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies |
| Q39820550 | Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience |
| Q50453183 | Misdiagnosing renal amyloidosis as minimal change disease |
| Q36519972 | Natural history and outcome of light chain deposition disease |
| Q55127439 | Novel Therapies in Light Chain Amyloidosis. |
| Q89575167 | Organ responses with daratumumab therapy in previously treated AL amyloidosis |
| Q30276115 | Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance |
| Q92600851 | Pathophysiology and management of monoclonal gammopathy of renal significance |
| Q38131710 | Pathophysiology and treatment of systemic amyloidosis |
| Q90115990 | Post-transplant Monoclonal Gammopathy of Renal Significance: A Case Series |
| Q50071663 | Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation |
| Q51692183 | Pulmonary masses in a patient with dyspnea: Apply Occam's razor or Hickam's dictum? |
| Q38613822 | Recent advances in the management of AL Amyloidosis |
| Q58853072 | Renal Transplantation in Systemic Amyloidosis-Importance of Amyloid Fibril Type and Precursor Protein Abundance |
| Q40261261 | Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy |
| Q53840060 | Renal outcomes of autologous stem cell transplantation among patients with light-chain amyloidosis: a single centre Spanish experience. |
| Q38168869 | Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions |
| Q99635469 | Survival Following Implantable Cardioverter-Defibrillator Implantation in Patients With Amyloid Cardiomyopathy |
| Q35026460 | The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients |
| Q64360352 | The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis |
| Q95660351 | The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis |
| Q36686965 | Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. |
Search more.